[1] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients. infected with 2019 novel coronavirus in Wuhan, China. Lancet. 395 (2020) 497–506.
[2] Coronavirus Outbreak Available at https://www.worldometers.info/coronavirus/.
Accessed 1 May,2020.
[3] Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM.Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 367(2012) 1814–1820.
[4] Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 382 (2020) 727–733.
[5] Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel. Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol 94 (2020).
[6] Li XC, Zhang J, Zhuo JL. The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacol Res . 125 (2017) 21–38.
[7] Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med Assoc. 323 (2020) 1061–1069.
[8] Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet . 395 (2020) 565–574.
[9] National health commission of China. Guideline of management of COVID-19 (version3)http://www.nhc.gov.cn/yzygj/s7653p/202001/f492c9153ea9437bb587ce2ffcbee1fa.shtml. Date last updated: January 23 2020.
[10] Lippi G, Wong J, Henry BM. Hypertension and its severity or mortality in. Coronavirus Disease 2019 (COVID-19): a pooled analysis. Polish Arch Intern Med. 2019 (2020).
[11] Te Riet L, Van Esch JHM, Roks AJM, Van Den Meiracker AH, Danser AHJ. Hypertension: Renin-Angiotensin-Aldosterone System Alterations. Circ Res. 116 (2015) 960–975.
[12] Klimas J, Olvedy M, Ochodnicka-Mackovicova K, et al. Perinatally. administered. losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats. J Cell Mol Med. 19 (2015) 1965–1974.
[13] Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol.203 (2004) 631–637.
[14] Antonio GE, Wong KT, Hui DSC, et al. Imaging of severe acute respiratory syndrome in Hong Kong. Am J Roentgenol .181 (2003) 11–17.
[15] Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020.
[16] Wong CK, Lam CWK, Wu AKL, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol.136 (2004) 95–103.
[17] Review I. Immune activation and inflammation in HIV-1 infection : 2008: 231–241.
[18] Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020.
[19] Mussap M, Degrandi R, Cataldi L, Fanos V, Plebani M. Biochemical markers for the early assessment of neonatal sepsis: the role of procalcitonin. J Chemother . 19 (2007) 35–38.
[20] Mugisho OO, Robilliard LD, Nicholson LFB, Graham ES, O’Carroll SJ. Bradykinin receptor-1 activation induces inflammation and increases the permeability of human brain microvascular endothelial cells. Cell Biol Int. 44 (2020) 343–351.
[21] Totura AL, Bavari S. Broad-spectrum coronavirus antiviral drug discovery. Expert Opin Drug Discov .14 (2019) 397–412.
[22] Kandeel M, Al-Nazawi M. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease. Life Sci. 251 (2020) 117627.
[23] Blaising J, Polyak SJ, Pecheur EI. Arbidol as a broad-spectrum antiviral: an update. Antiviral research. 107(2014) 84-94.
[24] National health commission of China. Guideline of management of COVID-19
(version7)http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc 7f5912eb1989.shtml. Date last updated: March 4 2020. Hui DS. Systemic Corticosteroid Therapy May Delay Viral Clearance in Patients with Middle East Respiratory Syndrome Coronavirus Infection. American journal of respiratory and critical care medicine. 197(2018) 700-701.
[25] Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with. Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis 2020.
[26] Falzarano D, De Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP, et al. Treatment with interferon-α2b and ribavirin improves outcome in ERS-CoV–infected rhesus macaques. Nature medicine. 19 (2013) 1313-1317.
[27] Faure E, Poissy J, Goffard A, Fournier C, Kipnis E, Titecat M, et al. Distinct immune. response in two MERS-CoV-infected patients: can we go from bench to bedside? PloS one. 9 (2014).
[28] Stockman LJ, Bellamy R, Garner P. SARS: Systematic review of treatment effects. PLoS Med. 3 (2006) 1525–1531.
[29] Hui DS. Systemic corticosteroid therapy may delay viral clearance in patients with middle east respiratory syndrome coronavirus infection. Am J Respir Crit Care Med. 197 (2018) 700–701.